Clinical Trials on HER2-mutant Non-Small Cell Lung Cancer in New Zealand

Total 1795 results

Enliven Therapeutics

Recruiting

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)

HER2-positive Metastatic Breast Cancer | HER2 Gene Mutation | HER2 Mutant Non-small Cell Lung Cancer | HER2 Amplification

Spain, United States, Korea, Republic of, Taiwan, Italy, Australia, France
Puma Biotechnology, Inc.

Completed

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

HER2-mutant Non-Small Cell Lung Cancer

United States, France
Novartis Pharmaceuticals

Active, not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EGFR-mutant Non-small Cell Lung Cancer

Taiwan, Germany, Canada, Italy, Singapore, Hong Kong
Memorial Sloan Kettering Cancer Center
AstraZeneca; Genentech, Inc.

Completed

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Non-small Cell Lung Cancer | EGFR-mutant Lung Cancers

United States
University of Sydney
AstraZeneca; Australasian Lung Cancer Trials Group

Active, not recruiting

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. (ILLUMINATE)

EGFR Mutant Advanced Non Small Cell Lung Cancer

Taiwan, Australia
AstraZeneca

Terminated

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1)

Small Cell Lung Cancer | Non-Small Cell Lung Cancer

United States, Taiwan, New Zealand, Spain
OncoMed Pharmaceuticals, Inc.
Novotech (Australia) Pty Limited

Completed

A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Australia, New Zealand, Spain
Daiichi Sankyo

Available

Medical Access Program for Patritumab Deruxtecan

Epidermal Growth Factor Receptor (EGFR)-Mutated Non Small Cell Lung Cancer

United States
Trans Tasman Radiation Oncology Group

Unknown

Hypofractionated Radiotherapy (Stereotactic) Versus Conventional Radiotherapy for Inoperable Early Stage I Non-small Cell Lung Cancer (NSCLC) (CHISEL)

Non Small Cell Lung Cancer

Australia, New Zealand
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Rutgers Cancer Institute...

Active, not recruiting

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

United States
Roswell Park Cancer Institute

Completed

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Bayer

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Hong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II

Non-small Cell Lung Cancer | Advanced Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute

Completed

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Gene Mutation

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors

Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers

United States, Netherlands
Checkpoint Therapeutics, Inc.

Terminated

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO)

Metastatic Non-squamous Non Small Cell Lung Cancer

Peru, Russian Federation, South Africa, New Zealand, Georgia, Thailand, Brazil, Malaysia
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Adult Solid Neoplasm

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell Carcinoma

United States
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer (PAINT)

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Malignant Neoplasm in the Brain | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma

United States
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
Roswell Park Cancer Institute

Completed

Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); Boehringer Ingelheim

Completed

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Mersana Therapeutics

Recruiting

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast Cancer

United States
BeiGene

Recruiting

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Advanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...

Australia, United States
Roswell Park Cancer Institute

Active, not recruiting

Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage I Non-Small Cell Lung Cancer AJCC v7 | Stage...

United States
Genentech, Inc.

Completed

A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors

Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma

United States
Imugene Limited

Active, not recruiting

A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Squamous Non-small-cell Lung Cancer | Large Cell Carcinoma Lung | Adenocarcinoma Lung

United States, Australia
Elephas
Beaufort CRO

Recruiting

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)

NSCLC | Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
Trans Tasman Radiation Oncology Group
Peter MacCallum Cancer Centre, Australia

Completed

Lung Tumour Volume Database

Non-Small Cell Lung Cancer

Singapore, Australia, New Zealand
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Terminated

Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer (EVENT)

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer

United States
Novartis Pharmaceuticals

Recruiting

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03)

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Colorectal Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal | Non-Small Cell Lung Carcinoma | KRAS G12C Mutant Solid Tumors

Korea, Republic of, Spain, Belgium, United States, France, Germany, Italy, Singapore
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC

Active, not recruiting

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Metastatic Non Small Cell Lung Cancer | Recurrent Non Small Cell Lung Cancer

United States
Beth Israel Medical Center
St. Luke's-Roosevelt Hospital Center

Terminated

Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO)

Nonsquamous Nonsmall Cell Neoplasm of Lung | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB/IV

United States
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...

United States
Shionogi

Completed

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | Stage IIIA Non Small Cell Lung Cancer | Stage IIIB Non Small Cell Lung Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy

Lung Non-Squamous Non-Small Cell Carcinoma | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV... and other conditions

United States
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Australia, Korea, Republic of, United Kingdom
Greg Durm, MD
AstraZeneca; Indiana University School of Medicine

Terminated

Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Minimal Residual Disease | NSCLC Stage IV | Nsclc | Metastatic Non Small Cell Lung Cancer

United States
Zealand University Hospital

Completed

Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer

Metastatic Nonsmall Cell Lung Cancer

Denmark
AstraZeneca

Completed

Osimertinib Study in Indian Patients

Non Small Cell Lung Cancer (NSCLC)

India
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States, Canada
Rasim Gucalp
Millennium Pharmaceuticals, Inc.

Terminated

Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Sun Farm Corporation
National Center for Complementary and Integrative Health (NCCIH)

Unknown

Effects of Selected Vegetable and Herb Mix (SV) on Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Lung Cancer | Non-small Cell Lung Cancer | Bronchioloalveolar Cancer

United States
Memorial Sloan Kettering Cancer Center
EARLY Labs

Recruiting

Using Urine Samples to Identify Lung Cancer

Non Small Cell Lung Cancer

United States
Columbia University

Not yet recruiting

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Non Small Cell Lung Cancer

United States

Clinical Trials on HER2-mutant Non-Small Cell Lung Cancer in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations